Basic Information
| LncRNA/CircRNA Name | circ_0109320 |
| Synonyms | |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | NA | Drug | Gefitinib | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qRT-PCR , RNase R treatment , circRNA Microarray |
| Sample | plasma samples |
| Expression Pattern | up-regulated |
| Function Description | In total, 52 NSCLC patients treated with gefitinib were included for analysis. 1,377 circRNAs were differentially expressed in gefitinib effective and ineffective groups, among which 989 circRNAs were up-regulated, and 388 circRNAs were down-regulated in the effective group. Furthermore, two differentially expressed circRNAs, hsa_circ_0109320 and hsa_circ_0134501, were validated by RT-qPCR in an independent cohort of 38 gefitinib-treated NSCLC patients. Elevated hsa_circ_0109320 was associated with longer PFS in gefitinib-treated NSCLC patients.Taken together, hsa_circ_0109320 may be a potential biomarker for the efficacy of EGFR-TKI in NSCLC patients. |
| Pubmed ID | 31285870 |
| Year | 2019 |
| Title | Circular RNA Profiling Identified as a Biomarker for Predicting the Efficacy of Gefitinib Therapy for Non-Small Cell Lung Cancer |
External Links
| Links for circ_0109320 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |